Pharma Rep Focus

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag tecvayli

J&J gets first approval for multiple myeloma bispecific Tecvayli

pharmaphorum

AUGUST 25, 2022

Johnson & Johnson has its first worldwide regulatory approval – in the EU – for Tecvayli, one of two much-anticipated bispecific antibodies the drugmaker has developed for patients with multiple myeloma. Tecvayli previously scored a priority medicines (PRiME) designation from the EMA and a breakthrough-therapy tag from the FDA.

FDA

FDA Marketing Safety Patients

CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision

pharmaphorum

JULY 25, 2022

The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for multiple myeloma , joining a growing group of BCMA-targeted therapies for the blood cancer. The post CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision appeared first on.

Medicine

Medicine FDA Recruitment Patients

J&J gets first approval for multiple myeloma bispecific Tecvayli

CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision

Stay Connected